- Previous Close
4.850 - Open
4.500 - Bid 4.260 x --
- Ask 4.330 x --
- Day's Range
4.260 - 4.500 - 52 Week Range
4.260 - 14.020 - Volume
19,600 - Avg. Volume
57,684 - Market Cap (intraday)
1.019B - Beta (5Y Monthly) -1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.480 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cryofocus Medtech (Shanghai) Co., Ltd., a medical device company, develops, produces, and sells minimally-invasive interventional cryotherapy products in the People's Republic of China. The company develops products in the areas of vascular interventional therapy for the treatment of atrial fibrillation, hypertension, and other cardiovascular diseases; and natural orifice transluminal endoscopic surgery for the treatment of urinary, respiratory, and digestive diseases. Its products include Bladder Cryoablation System, a cryotherapy device for the treatment of non-muscle-invasive bladder cancer; pulmonary nodule localization needle for CT-guided localization of lung nodules; endoscopic clip for anastomosis for the closure of soft tissue in digestive tract; and laparoscopic single port multi-channel access platform for laparoscopic surgery. The company's products also comprise wound retractors for small incision surgery and minimally invasive surgery; ureteral dilation balloon catheter for ureteral stricture; laparoscopic biopsy bag for biopsy; and laparoscopic surgical instrument for laparoscopy application. The company was incorporated in 2013 and is based in Shanghai, the People's Republic of China.
www.cryofocus.comRecent News: 6922.HK
View MorePerformance Overview: 6922.HK
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6922.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6922.HK
View MoreValuation Measures
Market Cap
1.16B
Enterprise Value
1.13B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
26.10
Price/Book (mrq)
9.20
Enterprise Value/Revenue
25.33
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-194.96%
Return on Assets (ttm)
-44.99%
Return on Equity (ttm)
-88.18%
Revenue (ttm)
53.53M
Net Income Avi to Common (ttm)
-104.36M
Diluted EPS (ttm)
-0.480
Balance Sheet and Cash Flow
Total Cash (mrq)
46.26M
Total Debt/Equity (mrq)
54.89%
Levered Free Cash Flow (ttm)
--